Post on 10-Apr-2022
transcript
INTERNATIONALCONGRESSON SPONDYLOARTHRITIDES
www.spa-congress.org
12TH
PROGRAMME
9 - 11 September 2021
www.spa-congress.org
Online Congress
12TH12TH
2 3www.spa-congress.org www.spa-congress.org
Organisation
PresidentRik Lories (Belgium)
Local Organising CommitteeDirk Elewaut (Belgium)
Filip Van den Bosch (Belgium)
Honorary Scientific CommitteeEric Veys (Belgium – Founder)
Herman Mielants (Belgium - Co-Founder)Paul Bowness (uK)
Jürgen Braun (Germany) Matthew Brown (Australia)
Robert Colbert (USA) Robert Inman (Canada)
Marjatta Leirisalo-Repo (Finland) Jose A. Lopez de Castro (Spain)
Désirée van der Heijde (The Netherlands) David Yu (USA)
Scientific CommitteeXenofon Baraliakos (Germany)
Maxime Breban (France)Rubén Burgos Vargas (Mexico)
Francesco Ciccia (Italy) Laura Coates (UK)
Maria-Antonietta D’Agostino (France) Atul Deodhar (USA)
Lianne Gensler (USA)Nigil Haroon (Canada)
Helena Marzo-Ortega (UK) Robert Landewé (The Netherlands)
Walter Maksymowych (Canada) John Reveille (USA)
Martin Rudwaleit (Germany) Percival Sampaio-Barros (Brazil)
Jose Scher (USA)Georg Schett (Germany)
Welcome Address
Dear colleagues and friends,
Unprecedented times… required unprecedented measures. Due to the worldwide pandemic, we were not be able to invite you all to the Twelfth International Congress on Spondyloarthritides in 2020, but will try to make it up now in September 2021.
The Belgian COVID-19 measures and internal rules of the University of Gent, allow us to welcome only a small number of participants to Gent. We therefore were forced to restrict the live congress to the Organising and Scientific Committees, the speakers and the sponsors, without whose support the organisation of this congress would not be possible.
However, we are pleased to announce that the congress will be livestreamed on an online platform where you and many international colleagues can tune in and view the talks in real-time or at a convenient time for a month after the congress dates. Furthermore, the platform will offer ample opportunity for networking.
The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters. To facilitate the organisation of a live event, the local and scientific organizers focused on excellent speakers from continental Western Europe. We have not forgotten our far-away friends and colleagues and hope to see you back in 2022 at the next full edition.
The programme for the 2021 congress will still offer a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics.
In 2018, the ‘Gent Oration’ was introduced, aimed to honor a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to invite Professor Maxime Dougados as the inaugural Gent orator in this second edition.
We hope to welcome you and meet you online at the Tweltfth International Congress on Spondyloarthritides and remain,
Yours sincerely,
Rik Lories, PresidentDirk Elewaut and Filip Van den Bosch, Local Organisers
4 5www.spa-congress.org www.spa-congress.org
Thursday 9 September
12.50 Welcome Address Rik Lories, Congress President
SESSION 1: Pain, the next frontier in spondyloarthritis
13.00 INV1 The molecular basis of sensitization and pain Annemarie Malfait, USA
13.30 INV2 Pain and consequences for SpA patients Annelies Boonen, The Netherlands
SESSION 2: Spondyloarthritis in the post-genetics, pre-personalized medicine era
14.00 INV3 Could genetics be useful for clinical practice? Maxime Breban, France
14.25 INV4 Syndromes and rare disease, a toolkit for understanding spondyloarthritis Corinne Miceli, France
14.50 INV5 Opportunities for early remission in spondyloarthritis: A long-lasting effect? Philippe Carron, Belgium
15.15 Coffee Break and ePoster Viewing
SESSION 3: Spondyloarthritis in the post-genetics, pre-personalized medicine era
15.45 INV6 Crystals as activator of immunity Bart Lambrecht, Belgium
16.15 INV7 Neutrophils and NETS as orchestrators of chronic inflammatory disease Martin Herrmann, Germany
Thursday 9 September
Selected Oral Presentations I
16.45 O1 Comprehensive epigenomic profiling reveals disease- specific chromatin states in ankylosing spondylitis Carla Cohen, UK
17.00 O2 Phenotypic, histologic and imagiologic characterization of transmembrane tumor necrosis factor transgenic mice Elsa Vieira-Sousa, Portugal
17.15 O3 MHC haplotype controls development of IL-23 minicircle- induced murine spondyloarthritis Joerg Ermann, USA
Keynote Lecture - The Ghent SpA Oration17.30 INV8 A journey of discovery through axial spondyloarthritis Maxime Dougados, France
18.15 End of day 1
6 7www.spa-congress.org www.spa-congress.org
Friday 10 September
Session 4: Chasing the ghost: Disease modification in axSpA
08.30 INV9 The translational rheumatologist’s view Georg Schett, Germany
09.00 INV10 The absolutely correct way to assess Disease Modification in 2021 Robert Landewé, The Netherlands
09.30 INV11 Lessons learnt from studies of Disease Modification to optimally manage patients in the clinic Denis Poddubnyy, Germany
10.00 Coffee Break and ePoster Viewing
Selected Oral Presentations II
10.30 O4 The ASAS-OMERACT core domain set for axial spondyloarthirtis Victoria Navarro Compán, Spain
10.45 O5 Co-medication with a csDMARD is associated with improved outcomes of TNF inhibitors in patients with axial spondylarthritis: Results from the EuroSpA collaboration Michael Nissen, EuroSpA Research Collaboration, on behalf of DANBIO, Denmark
11.00 O6 Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis: Baseline and two-year follow-up data from the Be-GIANT cohort Ann-Sophie De Craemer, Belgium
11.15 O7 Functional genomics of RUNX3 regulatory SNPs associated with ankylosing spondylitis Matteo Vecellio, UK & Italy
11.30 O8 Th17 expansion is partially inhibited by IL-23, where polyfunctional Th17-derived cells are amplified by cellular stress in psoriatic arthritis Carmel Stober, UK
Friday 10 September
11.45 O9 Gut-joint migratory T cells are cytokine competent and contribute to inflammation in the joint Adam Lefferts, USA
12.00 Lunch
Session 5: Novel technologies and innovations in pathogenesis
13.30 INV12 New imaging tools in spondyloarthritis Connie van der Laken, The Netherlands
13.55 NV13 The deep dive – Single cell sequencing Martin Guilliams, Belgium
14.20 INV14 The data analyst: How to link clinical observations with new knowledge generation Rachel Knevel, The Netherlands
Selected Oral Presentations III
14.45 O10 Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the ULTIMATE study Maria-Antonietta D’Agostino, Italy
15.00 O11 Interleukin-23 inhibitors and their apparent ineffectiveness in treating axial spondyloarthritis: A systematic review with meta-analysis Louise Vanhoutte, Belgium
15.15 O12 A first in disease phase 2a trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study) Paul Bowness, UK
15.30 O13 Metabolomics profiling of serum for biomarker discovery to identify psoriatic arthritis and ankylosing spondylitis Walter Maksymowych, Canada
15.45 O14 Dendritic cells influence T cell fate and pathogenicity in HLA-B27 transgenic rat model of spondyloarthritis Simon Glatigny, FranceFriday 10 September
8 9www.spa-congress.org www.spa-congress.org
Friday 10 September
16.00 Coffee Break and ePoster Viewing
Keynote Lecture – Basic Science16.30 INV15 Regulatory and memory T cells in immune-mediated disease Femke van Wijk, The Netherlands 17.15 End of day 2
Registration
Saturday 11 September
Session 6: Gut and SpA
08.30 INV16 Gut and SpA: New targets for treatment Francesco Ciccia, Italy
08.55 INV17 Fecal microbiota transplantation, lessons learned Speaker to be confirmed
09.20 INV18 Therapeutic impact of the microbiome, the IBD example Speaker to be confirmed
Selected Oral Presentations IV
09.45 O15 Factors associated with switching from one TNFi agent to another TNFi, or IL-17i agent in patients with ankylosing spondylitis John Reveille, USA
10.00 O16 Correspondence between patient-reported flare and disease activity score variation in axial spondyloarthritis Félicie Costantino, France
10.15 O17 CHOP deficiency does not prevent gut inflammation in experimental spondyloarthritis Fatemeh Navid, USA
10.30 O18 Novel use of specific drugs attenuates the pro-inflammatory cytokines IL-17A and IFN-gamma Rajinder Singh Andev, UK
10.45 O19 Neutrophil-derived MIF is a critical driver and potential therapeutic target in spondyloarthritis Akihiro Nakamura, Canada
11.00 Coffee Break and ePoster Viewing
10 11www.spa-congress.org www.spa-congress.org
Registration
Registration Fees Rates in EUR0Participant MD € 250,00Researcher non-MD* € 150,00 Medical student/resident* € 150,00Participant non-MD, industry participant € 400,00
*Immediately after signing up, send proof of your status to astrid@medicongress.com.
PaymentVisa, Mastercard and American Express are accepted.
Access to the Whova Event PlatformYou can use the event platform on desktop and on your smartphone. You will be notified when the event goes live.
RecordingsAll sessions will be recorded and added to the Whova Event Platform. So even if you are unable to tune in to the sessions in real-time, you can view them at any suitable time (up to one month after the congress dates).
Organisation and AdministrationMEDICONGRESSNoorwegenstraat 49B-9940 Evergem, BelgiumPhone: +32 (0)9 218 85 85Email: congresses@medicongress.com
Saturday 11 September
Session 7: New interdisciplinary perspectives for spondyloarthritis
11.30 INV19 Emerging imaging techniques in spondyloarthritis: Dual- energy computed tomography and new MRI sequences Lennart Jans, Belgium
11.55 INV20 Impact of comorbidities on clinical management Ennio Lubrano, Italy
12.20 INV21 In silico medicine – Beyond the frontier Liesbet Geris, Belgium
12.45 Closure of the Congress Rik Lories, Congress President
Platinum Sponsors
Gold Sponsor
Silver Sponsor